Title: Upregulation of histone-lysine methyltransferases plays a causal role in hexavalent chromium-induced cancer stem cell-like property and cell transformation.
Journal: Toxicology and applied pharmacology 20180301
Title: Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression.
Journal: Oncotarget 20160315
Title: Epigenetic silencing of microRNA-218 via EZH2-mediated H3K27 trimethylation is involved in malignant transformation of HBE cells induced by cigarette smoke extract.
Journal: Archives of toxicology 20160201
Title: Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.
Journal: Leukemia 20131201
Title: Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Journal: Lung cancer (Amsterdam, Netherlands) 20121101
Title: Targeting the enhancer of zeste homologue 2 in medulloblastoma.
Journal: International journal of cancer 20121015
Title: 3-Bromo-3-deazaneplanocin and 3-bromo-3-deazaaristeromycin: synthesis and antiviral activity.
Journal: Bioorganic & medicinal chemistry letters 20120815
Title: Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Journal: Molecular cancer therapeutics 20120801
Title: 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells.
Journal: International journal of cancer 20120601
Title: Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.
Journal: Oncogene 20120412
Title: The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
Journal: Expert review of hematology 20120401
Title: Derivation of new human embryonic stem cell lines reveals rapid epigenetic progression in vitro that can be prevented by chemical modification of chromatin.
Journal: Human molecular genetics 20120215
Title: Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells.
Journal: Blood 20120202
Title: Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats.
Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120201
Title: Cloning and characterization of polyA- RNA transcripts encoded by activated B1-like retrotransposons in mouse erythroleukemia MEL cells exposed to methylation inhibitors.
Journal: BMB reports 20120201
Title: Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120101
Title: The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.
Journal: PloS one 20120101
Title: Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells.
Journal: Circulation research 20111111
Title: (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells.
Journal: Carcinogenesis 20111001
Title: The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Journal: Blood 20110908
Title: PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.
Journal: Biochemical and biophysical research communications 20110513
Title: S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Journal: Breast cancer research and treatment 20110501
Title: Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
Journal: Haematologica 20110501
Title: Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2.
Journal: Biochemical pharmacology 20110215
Title: Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110201
Title: Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.
Journal: PloS one 20110101
Title: Polycomb target genes are silenced in multiple myeloma.
Journal: PloS one 20100101
Title: Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Journal: Molecular cancer therapeutics 20091201
Title: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Journal: Blood 20090924
Title: DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.
Journal: Molecular cancer therapeutics 20090601
Title: BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.
Journal: Breast cancer research : BCR 20090101
Title: DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications.
Journal: Cancer cell 20080601
Title: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
Journal: Genes & development 20070501
Title: Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)- RNAs hybridized to 3'-end flanking sequences of beta(major) globin gene.
Journal: Biochimica et biophysica acta 20050322
Title: John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity.
Journal: Nucleosides, nucleotides & nucleic acids 20050101
Title: Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine.
Journal: Antiviral chemistry & chemotherapy 20040101
Title: Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners.
Journal: European journal of biochemistry 20030901
Title: Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.
Journal: Antiviral research 20030101
Title: Identification of active antiviral compounds against a New York isolate of West Nile virus.
Journal: Antiviral research 20020701
Title: 3-deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice.
Journal: Antiviral research 20020701
Title: The role of the Type I interferon response in the resistance of mice to filovirus infection.
Journal: The Journal of general virology 20010601
Title: Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections.
Journal: Clinical microbiology reviews 20010401
Title: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor.
Journal: Antiviral research 20000201
Title: Carboxy terminal variants of Epstein-Barr virus-encoded latent membrane protein 1 during long-term human immunodeficiency virus infection: reliable markers for individual strain identification.
Journal: The Journal of infectious diseases 19990101
Title: Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: recent advances.
Journal: Nucleosides & nucleotides 19980101
Title: S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation.
Journal: Molecular pharmacology 19971201
Title: Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains.
Journal: Proceedings of the National Academy of Sciences of the United States of America 19950103
Title: Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication.
Journal: Antiviral research 19930701
Title: Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro.
Journal: Antiviral research 19900101
Title: Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives.
Journal: Antimicrobial agents and chemotherapy 19890801
Title: Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities.
Journal: Journal of medicinal chemistry 19890701
Title: 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60.
Journal: Biochemical and biophysical research communications 19860313
Title: Fiskus W, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 2009, 114(13), 2733-2743.
Title: Avan A, et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther. 2012 Aug;11(8):1735-46.
Title: Kikuchi J, et al. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer. 2012 Nov;78(2):138-43.
Title: Sun F, et al. Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus?. Eur J Pharm Sci. 2015 Sep 18;77:290-302.
Title: Siddiqi FS, et al. The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes. J Am Soc Nephrol. 2016 Jul;27(7):2021-34.
Title: Noriko Uchiyama, et al. Aristeromycin and DZNeP cause growth inhibition of prostate cancer via induction of mir-26a. Eur J Pharmacol. 2017 Oct 5;812:138-146.
Title: Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.
